Aclaris Therapeutics (ACRS) Cash from Financing Activities (2014 - 2026)

Aclaris Therapeutics' Cash from Financing Activities history runs 13 years deep, the most recent figure standing at $57.8 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 21111.27% year-over-year to $57.8 million in Q1 2026; TTM through Mar 2026 was $52.2 million, a 29.77% decrease from a year earlier, with the FY2025 full-year figure at -$5.9 million, down 107.86% from the prior year.
• Cash from Financing Activities grew to $57.8 million in Q1 2026 per ACRS's latest filing, from -$2.5 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $74.6 million in Q4 2024 and bottomed at -$3.0 million in Q3 2025.
• The 5-year median for Cash from Financing Activities is -$9000.0 (2025), against an average of $13.3 million.
• Across the five-year window, Cash from Financing Activities soared 152104.08% in 2024 and tumbled 13936.36% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at $37000.0 in 2022, then soared by 32.43% to $49000.0 in 2023, then surged by 152104.08% to $74.6 million in 2024, then tumbled by 103.4% to -$2.5 million in 2025, then soared by 2380.23% to $57.8 million in 2026.
• Per Business Quant, the three latest ACRS Cash from Financing Activities figures stand at $57.8 million (Q1 2026), -$2.5 million (Q4 2025), and -$3.0 million (Q3 2025).